NCT06042257 - Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Hyperactivity in Children With Down SyndromeImpulsivity in Children With Down Syndrome

Interventions

DRUG

Guanfacine Hydrochloride Immediate Release

0.5 mg capsules

DRUG

Placebo

Matching placebo capsule

Trial Locations (15)

21205

Kennedy Krieger Institute, Baltimore

23220

Virginia Center for Children, Richmond

27705

Duke University Hospital, Durham

28204

Atrium Health-Wake Forest School of Medicine, Charlotte

30322

Emory University, Atlanta

44308

Akron Children's Hospital, Akron

45229

Cincinnati Children's Hospital, Cincinnati

52242

University of Iowa, Iowa City

53792

University of Wisconsin Madison, Madison

60611

Ann and Robert H. Lurie Hospital of Chicago, Chicago

85016

Phoenix Childrens Hospital, Phoenix

98195

University of Washington, Seattle

06250

Yale University School of Medicine, New Haven

02115

Boston Children's Hospital, Boston

02421

Massachusetts General Hospital, Lexington

All Listed Sponsors

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Rachel G. Greenberg, MD, MB, MHS

OTHER